A new softer oral iron

A new softer oral iron

Supplied by Maltofer
Maltefor kitten
Maltofer, the softer oral iron

Introducing Maltofer® for the treatment and prevention of iron deficiency for patients who have trouble tolerating ferrous sulphates

Side effects to ferrous sulphates are common

Side effects to ferrous sulphates are common1

Your own clinical experience may tell you that important iron medications may often go unused because of gastrointestinal side effects. Let’s take a look at the adverse events recorded in a recent clinical trial to see if your clinical experience matches these findings.

In an exploratory, open-label, randomized, controlled, multicenter study undertaken in pregnant women with iron-deficiency anaemia. Patients were randomized 1:1 to Maltofer® (oral iron(III) polymaltose complex) or ferrous sulphate (each 100 mg iron twice daily) for 90 days.

RESULTS:
The primary endpoint, change in haemoglobin from baseline to days 60 and 90, did not differ significantly between treatment groups. The Maltofer® group showed a 21.6 g/L improvement in haemoglobin versus 19.3g/L for the ferrous sulphate group. However, adverse events were significantly less frequent in the Maltofer® group, occurring in 29.3% of patients, compared with 56.4% of patients in the ferrous sulphate group (p = 0.015)

What makes Maltofer different?

Maltofer’s® polymaltose shell facilitates active and controlled delivery of iron to the body, so there is a lower incidence of gastrointestinal-related side effects1,2

Other things you should know about Maltofer

Unlike ferrous sulphate Maltofer® can be taken with food. In fact, with Maltofer®,iron absorption is increased when taken with food3,4

  1. Unlike ferrous sulphate Maltofer® can be taken with food. In fact, with Maltofer®,iron absorption is increased when taken with food3,4
  2. Maltofer® has been introduced into more than 80 countries around the globe, including Australia
  3. Available as tablets or as a pleasant tasting syrup5
  4. It is manufactured in Switzerland
Abbreviated prescribing information
Maltofer® tablets (100mg iron as iron polymaltose) and syrup (50mg/5mL iron as iron polymaltose) is a Pharmacy Medicine for treatment of iron deficiency in adults/adolescents where use of ferrous iron supplements is not tolerated or inappropriate and for prevention of iron deficiency in adults/adolescents at high risk where the use of ferrous iron supplements is not tolerated or inappropriate. Dosage and administration: Dosage and duration on treatment depend upon extent of iron deficiency. Please refer to data sheet for full dosage recommendations. Precautions: Iron deficiency anaemia: all other causes of anaemia should be considered/treated prior to Maltofer use. Use with caution in patients with infections or tumour, regular monitoring of Hb and serum ferritin levels required to gauge response.
Pregnancy Category B1. Use in children <12 years not recommended, limited experience in elderly.

Contraindications: Known hypersensitivity to iron polymaltose, iron overload e.g. haemochromatosis, disturbances in iron utilisation, anaemia not caused by irondeficiency.

Adverse effects: Very common: discoloured stools. Common: diarrhoea, nausea, dyspepsia.

Interactions: Concomitant parenteral iron. Maltofer® is a registered trademark for Vifor Pharma used under licence by Aspen Pharmacare C/O Pharmacy Retailing (NZ) Ltd, Auckland. NZ-MAL-1900014 TAPS PP4472–AU19
References
  1. Ortiz R et al. J Matern Fetal Neonatal Med 2011;24:1–6.
  2. Geisser P and Burckhardt S.Pharmaceutics 2011;3:12-33
  3. Geisser P. Arzneimittelforschung 1990;40:754-60.
  4. Lundqvist H and Sjoberg F. Arzneimittelforschung 2007;57:401-16.
  5. Maltofer Data Sheet, June 2018